Eosinophilic Esophagitis (EoE) Food introduction-3rd dose ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastrointestinal disease | 1 |
98. Eosinophilic gastrointestinal disease
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05247866 (ClinicalTrials.gov) | June 16, 2022 | 21/12/2021 | Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis | Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis | Eosinophilic Esophagitis | Dietary Supplement: Eosinophilic Esophagitis (EoE) food introduction-1st;Dietary Supplement: Eosinophilic Esophagitis (E0E) food introduction-2nd;Dietary Supplement: Eosinophilic Esophagitis (EoE) Food introduction-3rd dose;Drug: Dupilumab | Children's Hospital of Philadelphia | Regeneron Pharmaceuticals;Genzyme, a Sanofi Company | Recruiting | 6 Years | 25 Years | All | 30 | Phase 4 | United States |